Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Avivagen Inc. (VIVXF : OTC)

• Company Description    Avivagen Inc. is a life-sciences company. It is engaged in developing and commercializing products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defences. Avivagen Inc. is based in Ottawa, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $0.00 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 Sussex Drive - Ottawa,A6 K1A 0R6 CAN ph: 613-702-2908 fax: - d.basek@avivagen.com http://www.avivagen.com

• General Corporate Information    Officers Kym Anthony - Chief Executive Officer and Chairman David Hankinson - Vice Chairman of the Board Chris Boland - Chief Financial Officer Aubrey Dan - Director Paul Mesburis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 05382F202 SIC: 8880 Fiscal Year Fiscal Year End: October Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/25 - - 01/31/25 - - 10/31/24 - - ROA 04/30/25 - - 01/31/25 - - 10/31/24 - - Current Ratio 04/30/25 - - 01/31/25 - - 10/31/24 - - Quick Ratio 04/30/25 - - 01/31/25 - - 10/31/24 - - Operating Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Net Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Pre-Tax Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Book Value 04/30/25 - - 01/31/25 - - 10/31/24 - - Inventory Turnover 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Capital 04/30/25 - - 01/31/25 - - 10/31/24 - -

Powered by Zacks Investment Research ©